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ABSTRACT
Introduction: While nausea and vomiting in early pregnancy are very common, affecting
approximately 80% of the pregnancies, hyperemesis gravidarum is a severe form affecting
0.3–1.0% of the pregnancies. Although hyperemesis gravidarum is rarely a source of mortality, it
is a significant source of morbidity. It is one of the most common indications for hospitalization
in pregnancy. Beyond the maternal and fetal consequences of malnutrition, the severity of
hyperemesis symptoms causes a major psychosocial burden leading to depression, anxiety, and
even pregnancy termination. The aim of this meta-analysis was to examine all randomized con-
trolled trials of interventions specifically for hyperemesis gravidarum and evaluate them based
on both subjective and objective measures of efficacy, maternal and fetal/neonatal safety, and
economic costs.
Material and methods: Randomized controlled trials were identified by searching electronic
databases. We included all randomized controlled trials for the treatment of hyperemesis gravi-
darum. The primary outcome was intervention efficacy as defined by severity, reduction, or ces-
sation in nausea/vomiting; number of episodes of emesis; and days of hospital admission.
Secondary outcomes included other measures of intervention efficacy, adverse maternal/fetal/
neonatal outcomes, quality of life measures, and economic costs.
Results: Twenty-five trials (2052 women) met the inclusion criteria but the majority of 18 differ-
ent comparisons described in the review include data from single studies with small numbers of
participants. Selected comparisons reported below: No primary outcome data were available
when acupuncture was compared with placebo. There was insufficient evidence to identify clear
differences between acupuncture and metoclopramide in a study with 81 participants regarding
reduction/cessation in nausea or vomiting (risk ratio (RR) 1.40, 95% CI 0.79–2.49 and RR 1.51,
95% CI 0.92–2.48, respectively). Midwife-led outpatient care was associated with fewer hours of
hospital admission than routine inpatient admission (mean difference (MD) 33.20, 95% CI
46.91 to 19.49) with no difference in pregnancy-unique quantification of emesis and nausea
(PUQE) score, decision to terminate the pregnancy, miscarriage, small-for-gestational age infants,
or time off work when compared with routine care. Women taking vitamin B6 had a slightly lon-
ger hospital stay compared with placebo (MD 0.80 days, 95% CI 0.08–1.52). There was insuffi-
cient evidence to demonstrate a difference in other outcomes including mean number of
episodes of emesis (MD 0.50, 95% CI 0.40–1.40) or side effects. A comparison between meto-
clopramide and ondansetron identified no clear difference in the severity of nausea or vomiting
(MD 1.70, 95% CI 0.15–3.55, and MD 0.10, 95% CI 1.63–1.43; one study, 83 women, respect-
ively). However, more women taking metoclopramide complained of drowsiness and dry mouth
(RR 2.40, 95% CI 1.23–4.69, and RR 2.38, 95% CI 1.10–5.11, respectively). There were no clear dif-
ferences between groups for other side effects. In a single study with 146 participants comparing
metoclopramide with promethazine, more women taking promethazine reported drowsiness, diz-
ziness, and dystonia (risk ratio (RR) 0.70, 95% CI 0.56–0.87, RR 0.48, 95% CI 0.34–0.69, and RR
0.31, 95% CI 0.11–0.90, respectively). There were no clear differences between groups for other
important outcomes including quality of life and other side effects. In a single trial with 30
women, those receiving ondansetron had no difference in duration of hospital admission com-
pared to those receiving promethazine (mean difference (MD) 0.00, 95% CI 1.39–1.39),
although there was increased sedation with promethazine (RR 0.06, 95% CI 0.00–0.94). Regarding
corticosteroids, in a study with 110 participants there was no difference in days of hospital
admission compared to placebo (MD 0.30, 95% CI 0.70–0.10), but there was a decreased
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readmission rate (RR 0.69, 95% CI 0.50–0.94; 4 studies, 269 women). For hydrocortisone com-
pared with metoclopramide, no data were available for primary outcomes and there was no dif-
ference in the readmission rate (RR 0.08, 95% CI 0.00–1.28; one study, 40 women). In a study
with 80 women, compared to promethazine, those receiving prednisolone had increased nausea
at 48h (RR 2.00, 95% CI 1.08–3.72), but not at 17 days (RR 0.81, 95% CI 0.58–1.15). There was no
clear difference in the number of episodes of emesis or subjective improvement in nausea/
vomiting.
Conclusions: While there were a wide range of interventions studied, both pharmaceutical and
otherwise, there were a limited number of placebo controlled trials. In comparing the efficacy of
the commonly used antiemetics, metoclopramide, ondansetron, and promethazine, the results of
this review do not support the clear superiority of one over the other in symptomatic relief.
Other factors such as side effect profile medication safety and healthcare costs should also be
considered when selecting an intervention.
Introduction
While nausea and vomiting in early pregnancy are
very common, affecting approximately 80% of the
pregnancies, hyperemesis gravidarum is a severe form
affecting 0.3–1.0% of the pregnancies [1,2]. The defin-
ition of hyperemesis gravidarum varies but generally
includes intractable nausea/vomiting, signs of dehydra-
tion such as ketonuria, high urine specific gravity, elec-
trolyte imbalances, and weight loss of at least 5% of
prepregnancy weight, excluding other diagnoses
[3–16]. The onset is generally in the first trimester at
six to eight weeks, peaking by 12 weeks, with most
women having resolution of symptoms by 20 weeks’
gestation [5,17–30].
Although hyperemesis gravidarum is rarely a source
of mortality, it is a significant source of morbidity. It is
one of the most common indications for hospitalization
in pregnancy [3]. Beyond the maternal and fetal conse-
quences of malnutrition, the severity of hyperemesis
symptoms causes a major psychosocial burden leading
to depression, anxiety, and even pregnancy termination
[3,6–9,31–45]. The socioeconomic costs of hyperemesis
are also significant, stemming from treatment expense,
lost job productivity, and high healthcare costs [8].
The objective of this review is to examine all the
randomized controlled trials of interventions specific-
ally for hyperemesis gravidarum and evaluate them
based on both subjective and objective measures of
efficacy, maternal and fetal/neonatal safety, and eco-
nomic costs.
Materials and methods
This review was performed according to a protocol
designed a priori and recommended for systematic
review by the Cochrane Library, and validated in prior
non-Cochrane meta-analyses [45–85]. We searched the
Cochrane Pregnancy and Childbirth Group’s (PCG)
Trials Register by contacting the Trials Search Co-ordi-
nator (up to date as of 20 December, 2015).
Briefly, the Cochrane PCG Trials Register is main-
tained by the Trials Search Co-ordinator and contains
trials identified from:
1. monthly searches of the Cochrane Central Register
of Controlled Trials (CENTRAL);
2. weekly searches of MEDLINE (Ovid);
3. weekly searches of Embase (Ovid);
4. monthly searches of CINAHL (EBSCO);
5. handsearches of 30 journals and the proceedings
of major conferences;
6. weekly current awareness alerts for a further 44
journals plus monthly BioMed, Central email alerts.
7. The World Health Organization International
Clinical Trial Registry Platform (ICTRP) and
ClinicalTrials.gov
In addition, we contacted the Cochrane
Complementary Medicine Field to search their Trials
Register (20 September 2014) and checked again via
The Cochrane Register of Studies (20 December
2015).
We included all randomized controlled trials of any
intervention for hyperemesis gravidarum. Trials that
reported in abstract were included, provided that
there was sufficient information in the abstract or
available from the author to allow us to assess eligibil-
ity and risk of bias. We excluded quasi-randomized tri-
als and trials using a cross-over design. Multiarmed
trials were included and pair-wise comparisons were
conducted separately. We excluded trials on nausea
and vomiting of pregnancy that were not specifically
studying the more severe condition of hyperemesis
gravidarum.
The outcomes below are slightly different from
what was initially published in the protocol for this
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review [10]. Severity of nausea/vomiting was added as
a primary outcome because it was found that this was
often what was reported in the included studies.
Similarly, rather than reporting the number of women
requiring additional antiemetics, the outcome “number
of antiemetics required” was used instead as this was
more often reported.
Primary outcomes
Intervention efficacy:
1. Severity, reduction, or cessation in nausea/
vomiting
2. Number of episodes of emesis
3. Days of hospital admission
Secondary outcomes
Intervention efficacy:
1. Hospital readmission
2. Number of women requiring additional
antiemetics
3. Need for enteral or parenteral nutrition
Adverse maternal outcomes:
1. Pregnancy complications (i.e. antepartum hemor-
rhage, preeclampsia, gestational hypertension)
2. Weight loss
Adverse fetal/neonatal outcomes:
1. Spontaneous abortion
2. Stillbirth and neonatal death
3. Congenital abnormalities
4. Low birthweight
5. Preterm birth
Quality of life:
1. Quality of life outcomes including emotional, psy-
chological, and physical well-being
2. Intervention side effects
3. Decision to terminate the pregnancy
Economic costs:
1. Direct financial costs to women
2. Productivity costs
3. Healthcare system costs
Data extraction
Selection of studies
Two review authors (RB and SB) independently
assessed for inclusion all the potential studies we iden-
tified as a result of the search strategy. We resolved
any disagreement through discussion, or if required,
we consulted a third author (AK).
Data extraction and management
We designed a form to extract data. Three review
authors (RB, SB, GS) extracted data using the agreed
form and resolved discrepancies either through discus-
sion or with consultation with a fourth author (AK).
We entered data into Review Manager software [11]
and checked for accuracy. When information regarding
any of the above was unclear, we attempted to con-
tact authors of the original reports to provide further
details.
Assessment of risk of bias in included studies
Two review authors (RB and SB) independently
assessed the risk of bias for each study using the crite-
ria outline in the Cochrane Handbook for Systematic
Reviews of Interventions [12]. We resolved any disagree-
ment by discussion or by involving an additional
assessor (AK).
Assessment of the quality of evidence using the
GRADE approach
The quality of the evidence has been assessed using
the GRADE approach as outlined in the GRADE
handbook [13] in order to assess the quality of the
body of evidence relating to the following
outcomes.
1. Severity, reduction or cessation in nausea/
vomiting
2. Number of episodes of emesis
3. Days of hospital admission
4. Intervention side effects
5. Quality of life outcomes including emotional, psy-
chological, and physical well-being
6. Pregnancy complications (i.e. antepartum hemor-
rhage, preeclampsia, gestational hypertension)
7. Adverse fetal/neonatal outcomes (i.e. spontan-
eous abortion, stillbirth and neonatal death, con-
genital abnormalities, low birthweight, preterm
birth).
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Measures of treatment effect
Dichotomous data
For dichotomous data, we presented results as sum-
mary risk ratio with 95% confidence intervals.
Continuous data
For continuous data, we planned to use the mean dif-
ference if outcomes were measured in the same way
between trials and the standardized mean difference
to combine trials that measured the same outcome,
but used different methods. We were unable to pool
continuous data because most trials had a unique
comparison, thus only the mean difference was used.
We assessed statistical heterogeneity in each meta-
analysis using the T2, I2 and Chi2 statistics. We
regarded heterogeneity as substantial if an I2 was
greater than 30% and either the T2 was greater than
zero, or there was a low p value (less than 0.10) in the
Chi2 test for heterogeneity.
We carried out statistical analysis using the Review
Manager software [11]. We used fixed-effect meta-ana-
lysis for combining data where it was reasonable to
assume that studies were estimating the same under-
lying treatment effect: i.e. where trials were examining
the same intervention, and the trials’ populations and
methods were judged to be sufficiently similar. If there
was clinical heterogeneity sufficient to expect that the
underlying treatment effects differ between trials, or if
substantial statistical heterogeneity was detected,
we used random-effects meta-analysis to produce an
overall summary, if an average treatment effect across
trials was considered clinically meaningful. The ran-
dom-effects summary was treated as the average
range of possible treatment effects and we discussed
the clinical implications of treatment effects differing
between trials. If the average treatment effect was not
clinically meaningful, we did not combine trials.
Where we used random-effects analyses, we pre-
sented the results as the average treatment effect with
95% confidence intervals, and the estimates of T2
and I2.
Results
The search strategy identified 78 total reports repre-
senting 67 distinct studies (some studies were resulted
in more than one publication). Of these 67 studies, 25
met inclusion criteria for the review, 35 were excluded,
2 are awaiting translation and 5 studies are ongoing
(Figure 1). See supplementary Appendix A for a full
table of descriptions of the included studies.
This review included 25 studies (involving 2052
women), but the majority of our analyses are based
on data from single studies with small numbers of par-
ticipants. The included studies covered a range of
interventions (both pharmacologic and nonpharmaco-
logical, such as acupressure/acupuncture, outpatient
care, intravenous fluids, and various pharmaceutical
interventions) for treating hyperemesis gravidarum.
The methodological quality of the included studies
varied (Figure 2).
Table 1 lists all 18 comparisons with all primary
outcomes and selected secondary outcomes. For a
full report of all comparisons and outcomes, see sup-
plementary Appendix B.
A broad range of interventions for hyperemesis
gravidarum were examined in the included trials and
so to summarize findings, we selected those nonphar-
macological and pharmacologic comparisons that we
considered to be most clinically relevant to be
reported here.
Figure 1. Study flow diagram.
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Figure 2. (A) Risk of bias graph about each risk of bias item presented as percentages across all included studies. (B) Assessment
of risk of bias in included studies.
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The comparisons selected for presentation here are:
1. Acupuncture versus placebo
2. Acupuncture versus metoclopramide
3. Midwife led outpatient care versus routine care
4. Pyridoxine versus placebo
5. Metoclopramide versus ondansetron
6. Hydrocortisone versus metoclopramide
7. Metoclopramide versus promethazine
8. Ondansetron versus promethazine
9. Corticosteroid versus placebo
10. Corticosteroids versus promethazine
Acupuncture and acupressure versus placebo
Three studies (182 women) compared P6 acupressure
or acupuncture versus placebo and were included in
the analysis [14–16].
Two additional studies were in abstract form only
and did not have data that could be entered into the
analysis. Miller et al. compared nerve stimulation with
a watch-like device at P6 versus placebo and reported
lower symptoms in the intervention group, without
specific data reported [17].
Mamo et al. compared acupressure Sea-band
applied to each wrist versus control with no acupres-
sure and reported more women required additional
antiemetics than in the control group, again without
specific data reported [18].
Primary outcomes
Severity, reduction, or cessation in nausea/vomiting.
Only one study reported a decreased mean nausea
score (using Rhodes index of nausea vomiting or
retching), however, no standard deviation was
reported so this could not be entered into our data
and analysis tables [14].
Secondary outcomes
The number of women requiring additional antiemet-
ics was lower in the acupuncture/acupressure group
compared to placebo (RR 0.20, 95% confidence inter-
val (CI) 0.08–0.50) [15]. However, there was no differ-
ence between the treatment group and placebo
control with regard to spontaneous abortion (RR 0.48,
95% CI 0.05–5.03, low-quality evidence) [16], preterm
birth less than 37 weeks (RR 0.12, 95% CI 0.01–2.26
low-quality evidence), stillbirth or neonatal death (RR
0.57, 95% CI 0.04–8.30, low-quality evidence) [16], deci-
sion to terminate the pregnancy (RR 0.72, 95% CI
0.18–2.95) [16], or anxiodepressive symptomology (RR
1.01, 95% CI 0.73–1.40, very low-quality evidence) [15].
Acupuncture versus metoclopramide
One study (81 women), evaluated the efficacy of acu-
puncture twice weekly versus metoclopramide
infusion [19].
Primary outcomes
Severity, reduction, or cessation in nausea/vomiting.
After the cessation of the last treatment, there was no
difference in the rate of women who experienced a
reduction of nausea (RR 1.40, 95% CI 0.79–2.49, very
low-quality evidence) or the rate of women who experi-
enced a reduction in vomiting (RR 1.51, 95% CI
0.92–2.48, very low-quality evidence).
Midwife led outpatient care versus routine care
One study (53 women) randomized women to midwife
led outpatient care versus routine care with hospital
admission. Data were obtained from communication
with the authors [20].
Primary outcomes
Severity, reduction, or cessation in nausea/vomiting.
There was no clear differences in the mean PUQE
(pregnancy-unique quantification of emesis and nau-
sea) score between the group of women who received
midwife-led outpatient care and women who received
routine care with admission (MD 0.70 points, 95% CI
3.17–1.77).
Days of hospital admission. Women who received
midwife-led care remained in the hospital for fewer
hours (MD 33.20 h, 95% CI 46.91 to 19.49)
Secondary outcomes
There was no clear difference in the rate of women
who decided to terminate the pregnancy (RR 2.89,
95% CI 0.12–67.96). There was also no clear difference
in spontaneous miscarriage (RR 0.96, 95% CI
0.15–6.34), or in the rate of small-for-gestational-age
infants (RR 1.44, 95% CI 0.26–7.96). In terms of eco-
nomic costs there was also no evidence of a difference
between groups in relation to the rate of women who
lost time from paid employment (RR 1.04, 95% CI
0.28–3.87).
Pyridoxine versus placebo
One study (94 women) randomized women to receive
pyridoxine 20mg orally three times a day versus pla-
cebo, in addition to all women receiving standard care
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with intravenous rehydration, metoclopramide, and
oral thiamine. Interventions were continued for 2
weeks, outcomes examined at the one- and 2-week
mark, results reported here are at the 1-week mark
due to significant attrition by two weeks [21].
Primary outcomes
Severity, reduction, or cessation in nausea/vomiting
Tan, et al reported nausea score as a median rather
than a mean score – so the data could not be used
for the RevMan tables, however the trialist reported no
significant difference in nausea scores [21].
Number of episodes of emesis
There was no strong evidence of a difference in the
daily mean vomiting episodes (MD 0.50 vomiting epi-
sodes, 95% CI 0.40–1.40, low-quality evidence).
Days of hospital admission
There was a slightly longer hospital stay associated
with B6 compared with placebo (MD 0.80 days, 95% CI
0.08–1.52, moderate-quality evidence).
Secondary outcomes
There was no clear difference in hospital readmission
(RR 1.78, 95% CI 0.85–3.71) or in weight loss after 1
week (MD 0.00 kg, 95% CI 0.93–0.93). Quality of life
was reported as a median and therefore could not be
included in the analysis, however, the authors reports
no difference between groups in well-being score. Tan
et al. did report on intervention side effects, and there
was no differences in the rate of dizziness (RR 1.67,
95% CI 0.85–3.26, low-quality evidence), headaches, (RR
1.33, 95% CI 0.52–3.42, low-quality evidence), diarrhea
(RR 3.00, 95% CI 0.13–71.07), palpitations (RR 1.00,
95% CI 0.22–4.60, low-quality evidence) and dry mouth
(RR 0.82, 95% CI 0.49–1.38, low-quality evidence) in the
pyridoxine group compared to placebo after 1 week
of treatment. There were also no cases of rash or
photosensitivity in either group.
Metoclopramide versus ondansetron
There were two studies (243 women) that compared
metoclopramide with ondansetron. Abas et al. used
10mg intravenous metoclopramide every 8 h for four
doses versus 4mg ondansetron intravenous every 8 h
for four doses, while Kashifard et al. used oral medica-
tions in the same doses for 2 weeks and assessed
severity of nausea and vomiting during the treatment
period and 2 days 1 week after completion of therapy
[22,23].
Primary outcomes
Severity, reduction, or cessation in nausea/vomiting.
Abas et al. reported nausea score as a median so it
could not be analyzed in combination with the other
study, but they report no significant difference
between groups [22]. Kashifard, et al reported no sig-
nificant difference between the metoclopramide and
ondansetron groups in severity of nausea (MD 1.70
point, 95% CI 0.15–3.55, very low-quality evidence), or
in severity of vomiting according to a 10-point VAS
rating score on the second day 1 week after comple-
tion of therapy (MD 0.10 points, 95% CI 1.63–1.43,
very low-quality evidence) [23].
Secondary outcomes
Abas et al. provided data (from 160 women) in relation
to intervention side effects. The number of women
who felt drowsy (RR 2.40, 95% CI 1.23–4.69 moderate-
quality evidence), and who had a dry mouth (RR 2.38,
95% CI 1.10–5.11, moderate-quality evidence) was
higher in the metoclopramide group compared to the
group of women who received ondansetron. There
were no clear differences in the rate of women unable
to sleep (RR 1.29, 95% CI 0.50–3.28), felt dizzy (RR 2.33,
95% CI 0.94–5.77, low-quality evidence), had diarrhea
(RR 9.00, 95% CI 0.49–164.46), had headache (RR 1.22,
95% CI 0.54–2.79), experienced palpitations (RR 2.50,
95% CI 0.50–12.51), or noticed skin rash (RR 1.00, 95%
CI 0.06–15.71); no cases of dystonia in both groups
were reported [22]. Kashifard et al. reported no side
effects in either the metoclopramide or the ondanse-
tron group, although the side effects examined were
not specified [23]. In addition, Abas, et al reported no
difference in the well-being VNRS score about quality
of life outcome (MD 0.40 points, 95% CI 0.83–0.03,
moderate-quality evidence) [22].
Metoclopramide versus promethazine
One study (152 women) compared 10mg intravenous
metoclopramide versus 25mg intravenous prometha-
zine given eight hourly for 24 h [24].
Primary outcomes
Severity, reduction, or cessation in nausea/vomiting.
Nausea score was reported by as a median so data
could not be included in our analysis, but the trialist
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reported no significant difference in nausea score
between groups [24].
Number of episodes of emesis. The number of vomit-
ing episodes were as a median so these data could
not be included in our analysis, but the trialist
reported no significant difference in the number of
vomiting episodes between groups [24].
Secondary outcomes
In relation to quality of life, the mean well-being VNRS
score was similar in the metoclopramide group and
the promethazine groups (MD 0.50 points, 95% CI
0.22–1.22, low-quality evidence). Tan et al. also pro-
vided data on the intervention side effects – the num-
ber of women who felt drowsy (RR 0.70, 95% CI
0.56–0.87, moderate-quality evidence), dizzy (RR 0.48,
95% CI 0.34–0.69, moderate-quality evidence) and expe-
rienced dystonia (RR 0.31, 95% CI 0.11–0.90) was lower
in the metoclopramide group compared to the pro-
methazine group. Aside from that, there was no strong
evidence showing any differences in the number of
women unable to sleep (RR 0.78, 95% CI 0.40–1.53),
had a dry mouth (RR 0.91, 95% CI 0.62–1.34), had diar-
rhea (RR 1.39, 95% CI 0.32–5.99), had headache (RR
0.81, 95% CI 0.47–1.38) (low-quality evidence for the
aforementioned side effects), experienced palpitations
(RR 0.61, 95% CI 0.25–1.46), and noticed skin rash (RR
1.39, 95% CI 0.32–5.99).
Ondansetron versus promethazine. One study (30
women) randomized women to receive either 10mg
intravenous ondansetron or 50mg intravenous pro-
methazine for one dose then every 8 h as needed [25].
Primary outcomes
Severity, reduction, or cessation in nausea/vomiting.
Specific subjective nausea scores were not reported
and could not be entered into our RevMan tables.
However, the trialist reported no significant difference
in the severity of nausea between the two groups [25].
Days of hospital admission. There was no difference
between the ondansetron and promethazine groups in
terms of the number of days of hospital admission
(MD 0.00 days, 95% CI 1.39–1.39 very low-quality
evidence).
Secondary outcomes
Regarding secondary outcomes, the rate of sedation
(adverse effect) was increased with promethazine
(RR 0.06, 95% CI 0.00–0.94, low-quality evidence), no
other side effects were observed.
Corticosteroids versus placebo
There were four studies (271 women) that evaluated
the efficacy of steroids versus placebo in hyperemesis
gravidarum [26–29]. The specific medication and dose
varied by study – Duggar, et al studied oral methyl-
prednisone 12 tablets of 4mg methylprednisone daily
for 3 days followed by a 10-day taper [26]; Nelson-
Piercy et al. studied 20mg of oral prednisolone every
12 h for 1 week; they also provided additional antie-
metics as deemed necessary by the providers [27]; and
both Tabatabaii et al. and Yost et al. studied 125mg
of intravenous methylprednisolone followed by an oral
prednisone taper; in the former study the women also
received B6, in the latter study the women also
received metoclopramide and promethazine as stand-
ard of care [28,29].
Primary outcomes
Severity, reduction, or cessation in nausea/vomiting.
Nelson-Piercy et al reported a nonsignificant reduction
in severity of nausea in the steroid versus placebo
group, however this was reported as a median and
could not be included into the analysis [27].
Days of hospital admission
Days of hospital admission were available only from
Yost et al.; there was no clear difference (MD 0.30
days, 95% CI 0.70–0.10, very low-quality evidence) in
the number of days of hospital admission between
groups [29].
Secondary outcomes
Regarding secondary outcomes, the rate of hospital
readmission was lower in the steroid hormone group
compared to the placebo group of women (RR 0.69,
95% CI 0.50–0.94, four studies, 269 women) [26–29].
There was no difference in the rate of pregnancy com-
plications (pregnancy hypertension or gestational dia-
betes (RR 0.61, 95% CI 0.26–1.47, very low-quality
evidence) based on one study (110 women) [29]. There
was no significant difference in the rate of spontan-
eous abortion (RR 0.64, 95% CI 0.11–3.70 (one study,
110 women, very low-quality evidence) [29]. There was
no difference in the rate of stillbirth or neonatal death
(RR 0.70, 95% CI 0.09–5.29, 2 studies, 134 women, very
low-quality evidence) [27,29]. Only one study reported
on congenital abnormalities, and there was no
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difference between groups (RR 0.32, 95% CI 0.01–7.73,
one study 110 women, very low-quality evidence) [29].
One study reported on low birthweight (RR 1.35, 95%
CI 0.46–4.00, 110 women), very low-quality evidence)
[29] and another study reported on small-for-gesta-
tional-age infants (RR 1.00, 95% CI 0.07–14.21, 24
women) [27] and there was no significant difference
between groups for either outcome. One study
reported on preterm birth less than 36 weeks and
another reported on preterm birth less than 37 weeks,
when we combined these data using a random-effects
analysis (due to substantial statistical heterogeneity)
there was no difference between groups (average RR
1.01, 95% CI 0.31–3.28; two studies, 134 women,
Tau2¼ 0.27, I2¼ 37%), very low-quality evidence)
[27,29]. Duggar et al. reported intervention side effects
(specifics side effects not reported) and found no dif-
ference in the rate of side effects (RR 0.79, 95% CI
0.06–11.20, 25 women, very low-quality evidence) [26].
One study reported on the number of women requir-
ing additional antiemetics and there was no clear dif-
ference between groups for this outcome (RR 0.56,
95% CI 0.26–1.17, 24 women) and there was also no
difference in the number of women who decided to
terminate the pregnancy (RR 0.33, 95% CI 0.01–7.45,
24 women) [27].
Corticosteroids versus promethazine
Two studies (120 women) were involved in this com-
parison. One study evaluated oral methylprednisolone
16mg three times daily versus oral promethazine
25mg three times daily [30], while another one com-
pared 5mg oral prednisolone with 75mg oral pro-
methazine daily for 10 days [31].
Primary outcomes
Severity, reduction, or cessation in nausea/vomiting.
In one study the number of women with severe nau-
sea at 48 h was higher in the prednisolone group com-
pared to the promethazine group (RR 2.00, 95% CI
1.08–3.72, low-quality evidence) and at day 17 was not
significantly different between groups (RR 0.81, 95% CI
0.58–1.15, very low-quality evidence) [31]. We did not
find any difference in the number of episodes of vom-
iting at 48 h (RR 3.00, 95% CI 0.33–27.63) and at 17
days (RR 1.00, 95% CI 0.21–4.65, very low-quality evi-
dence) [31].
Another study reported on therapy failure as
defined by persistence of vomiting more than five
times/day, inability to tolerate liquids, and the wom-
en’s impression that they were not better, and there
was no difference between groups (RR 1.50, 95% CI
0.28–8.04) [30].
Number of episodes of emesis. Ziaei et al. reported
increased number of episodes of emesis in the pred-
nisolone group at 48 h, but no difference at day 17;
however, data were reported as a median so were not
able to be analyzed [31].
Secondary outcomes
Regarding secondary outcomes, there was no strong
evidence of differences in the rate of hospital readmis-
sion (RR 0.09, 95% CI 0.01–1.53), in the number of
women requiring additional antiemetics (RR 1.50, 95%
CI 0.28–8.04), or in the rate of stillbirth/neonatal death
(RR 3.00, 95% CI 0.13–69.52, low-quality evidence), in
the rate of preterm birth (RR 3.00, 95% CI 0.13–69.52,
low-quality evidence), or in the rate of women who
decided to terminate the pregnancy (RR 3.00, 95% CI
0.13–69.52) [30]. In terms of side effects, there was no
difference in the rate of women who felt abdominal
pain during the first 48 h (RR 0.33, 95% CI 0.07–1.55),
and between the third and 10th day (RR 0.11, 95% CI
0.10–2.00). The rate of drowsiness was also not sub-
stantially different (RR 0.08, 95% CI 0.00–1.32, low-qual-
ity evidence). Regarding quality of life, the number of
women who reported becoming well or partially well
by 48 h was lower in the prednisolone group com-
pared to promethazine (RR 0.67, 95% CI 0.47–0.95),
while no difference was identified in the number of
women who reported becoming well or partially well
by 17 days (RR 1.67, 95% CI 0.95–2.92) [31].
Hydrocortisone versus metoclopramide
There was one study (40 women) that compared
women receiving 300mg intravenous hydrocortisone
daily for 3 days, tapered over the week, versus 10mg
of metoclopramide intravenously three times daily for
one week [32].
Primary outcomes
Number of episodes of emesis. Mean number of daily
episodes of emesis were reported by as significantly
decreased in the hydrocortisone group, although the
actual numbers were not available to be included into
the analysis [32].
Secondary outcomes
Regarding secondary outcomes, there was no differ-
ence in the rate of hospital readmission between the
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metoclopramide and hydrocortisone groups (RR 0.08,
95% CI 0.00–1.28, moderate-quality evidence). Similarly,
there was no clear difference in the number of women
requiring enteral or parenteral nutrition between the
two groups (RR 0.33, 95% CI 0.01–7.72) [32].
Comment
On the basis of this review, there is little high-quality
and consistent evidence supporting any one interven-
tion over another, which should be taken into account
when making management decisions. Few interven-
tions were compared with placebo, and most were
compared with another intervention. While studies on
nonpharmacological interventions were limited, the
finding that midwife-led outpatient care compared to
inpatient hospitalization had similar outcomes with
decreased hours in the hospital warrants further inves-
tigation. The commonly used antiemetics ondansetron,
metoclopramide, and promethazine were not found to
have significant differences compared to each other in
symptomatic relief with differences primarily seen in
side-effect profile.
Limited data were available regarding adverse
maternal and neonatal outcomes, thus the lack of
report on adverse events or the lack of statistical sig-
nificance does not necessarily mean no harm is pre-
sent. Larger studies on individual interventions need
to be examined to determine the safety of these many
interventions.
There was also very limited reporting on the eco-
nomic impact of hyperemesis gravidarum and the
impact on this economic burden that interventions
may have. Although studies often reported an overall
well-being score, this does not necessarily equate with
ability to return to work.
There are a number of strengths to this review. The
main strength of this review is its comprehensive
approach to analyzing interventions specific to hyper-
emesis gravidarum. There are several other reviews
and overviews on hyperemesis gravidarum, with vary-
ing degrees of support from the literature [5,33–39].
This review is unique in the breadth of the interven-
tions examined, the limitation to only randomized con-
trolled trials, and examination interventions specifically
for hyperemesis gravidarum, versus the more common
and milder condition of nausea and vomiting in preg-
nancy. In addition, we attempted to be as inclusive as
possible in the search strategy and have included
studies in languages other than English.
This review has some limitations. The studies
reported are predominantly from European and North
American journals, which may limit the external
validity of these results. Interpreting and comparing
the findings of the studies included was difficult
because of the variation in the reporting of the sub-
jective outcome of severity of nausea and vomiting,
thus the meta-analysis component of this review is
limited. In addition, even within a comparison, often
dosages or route of administration varied between
studies, we treated them as equivalent which is not
necessarily clinically true. Finally, inclusion criteria were
defined by the study authors and varied by study as
there is no single standard definition or clinical criteria
for the diagnosis of hyperemesis gravidarum.
The difficulty in interpreting the results of this review
highlights the importance of having a specific definition
of hyperemesis gravidarum for use in trials, conducting
randomized controlled trials in comparing interven-
tions, and using validated instruments for the measure-
ment of severity of nausea and vomiting. There should
be an agreed-upon set of clearly-defined and measur-
able outcomes in trials of interventions for hyperemesis
gravidarum, so that outcomes of trials can be combined
in future meta-analyses. Furthermore, the clinical prac-
tice of managing patients with hyperemesis gravidarum
often employs combinations of interventions, which
have not been well studied.
While there are a wide range of interventions
studied, both pharmaceutical and otherwise, the most
common antinausea medications studied and found to
have some benefit in the treatment of hyperemesis
gravidarum are metoclopramide, ondansetron, and
promethazine. The results of this review do not sup-
port the clear superiority of one over the other in
symptomatic relief, as such, other factors such as side
effect profile, medication safety, and healthcare costs
should also be considered when selecting an
intervention.
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